PHRM Stock Overview
A specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PharmaTher Holdings Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.24 |
| 52 Week High | CA$0.43 |
| 52 Week Low | CA$0.14 |
| Beta | 3.41 |
| 11 Month Change | 11.36% |
| 3 Month Change | 13.95% |
| 1 Year Change | 53.13% |
| 33 Year Change | -39.51% |
| 5 Year Change | n/a |
| Change since IPO | 25.64% |
Recent News & Updates
Shareholder Returns
| PHRM | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 11.4% | -6.9% | 2.2% |
| 1Y | 53.1% | -22.8% | 23.4% |
Return vs Industry: PHRM exceeded the Canadian Pharmaceuticals industry which returned -22.8% over the past year.
Return vs Market: PHRM exceeded the Canadian Market which returned 23.4% over the past year.
Price Volatility
| PHRM volatility | |
|---|---|
| PHRM Average Weekly Movement | 19.9% |
| Pharmaceuticals Industry Average Movement | 12.0% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: PHRM's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: PHRM's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Fabio Chianelli | www.pharmather.com |
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company’s product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson’s disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia and procedural sedation. It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures.
PharmaTher Holdings Ltd. Fundamentals Summary
| PHRM fundamental statistics | |
|---|---|
| Market cap | CA$21.69m |
| Earnings (TTM) | -CA$2.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.0x
P/E RatioIs PHRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHRM income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.16m |
| Earnings | -CA$2.16m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PHRM perform over the long term?
See historical performance and comparison